While we execute on our global launch of ONPATTRO, our medical affairs and commercial teams also remain committed to addressing the challenge of raising disease awareness and improving diagnosis of hATTR amyloidosis. We continue to believe that hATTR amyloidosis is an under-diagnosed disease where improved medical education and diagnosis will help patients reach treatment options faster. As we've highlighted previously, our Alnylam Act program is a third party genetic screening initiative aimed at facilitating diagnosis of patients suspected of having hereditary ATTR amyloidosis.